Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 4, 2018
Reporting Period: Events occurring between September 25, 2018, and October 5, 2018.
Key Financial Metrics and Capital Structure Changes
This filing reports specific capital transactions rather than standard operating financial metrics (revenue, profit, cash flow). The filing text does not provide a clear value for revenue, profit, margins, or total liquidity.
- Debt-to-Equity Conversion: Issued 493,670 shares of common stock to settle $532,129 of outstanding indebtedness (including accrued interest and fees).
- New Debt Issuance: Issued convertible promissory notes with an aggregate principal amount of $160,000.
Material Changes and Transaction Details
The primary material change involves the restructuring of liabilities through equity issuance and the raising of new capital via convertible notes.
Convertible Note Terms
- $60,000 Portion: Convertible at $2.00 per share for the first six months; thereafter, conversion price is generally 58% of the fair value of common stock.
- $100,000 Portion: Convertible after 180 days at a price generally equal to 58% of the fair value of common stock.
Management Commentary, Risks, and Contingencies
Regulatory Basis: The Company relied on Section 4(a)(2) of the Securities Act of 1933 (transactions not involving a public offering) and Section 3(a)(9) (exchange with existing security holders) for these issuances.
Investor Status: The Company reasonably believes all investors are accredited investors. No general solicitation or advertising was used.
Risks: The filing does not explicitly list new risks, though the issuance of convertible notes with a 58% discount to fair value implies potential future dilution for existing shareholders.
Key Facts for Investor Verification
- Verify the impact of the 493,670 new shares on total outstanding share count and potential dilution.
- Confirm the total outstanding debt remaining after the $532,129 settlement and the addition of the $160,000 in new notes.
- Review the "fair value" determination methodology for the 58% conversion price to assess future dilution scenarios.
- Check subsequent filings for the actual conversion of the $160,000 notes into equity.